GlobeNewswire Inc.··Arvinas, Inc.Arvinas Wins FDA Nod for First PROTAC Breast Cancer Drug
Arvinas and Pfizer secure FDA approval for VEPPANU, the first PROTAC protein degrader, for ESR1-mutated breast cancer based on Phase 3 data showing 43% progression-risk reduction.
PFEARVNFDA approvalbreast cancer